about
Fruit juice inhibition of uptake transport: a new type of food-drug interactionTime effects of food intake on the pharmacokinetics and pharmacodynamics of quazepamPharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsSilymarin glyceryl monooleate/poloxamer 407 liquid crystalline matrices: physical characterization and enhanced oral bioavailability.A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.The effect of food on the pharmacokinetics of oral fluralaner in dogsPossible interactions between dietary fibres and 5-aminosalicylic acid [corrected]Influence of dietary substances on intestinal drug metabolism and transport.Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase.Clinical studies with oral lipid based formulations of poorly soluble compoundsThe effect of food components on the absorption of P-gp substrates: a review.Islamic fasting and multiple sclerosis.A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumorsAntihypertensive therapy: special focus on drug interactions.Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using 18F-SP203Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Interaction of warfarin with drugs, natural substances, and foods.Challenges and opportunities in achieving bioequivalence for fixed-dose combination products.Probiotics, prebiotics, and synbiotics: gut and beyondMechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects.Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunctionSingle-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsEffects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.Biomagnetic methods: technologies applied to pharmaceutical research.The role of diet on the clinical pharmacology of oral antineoplastic agents.Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters.The pharmacology of novel oral anticoagulants.Recent advancements in mechanical reduction methods: particulate systems.Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population.Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.Single-dose safety, pharmacokinetics, and food effects studies of compound naphthoquine phosphate tablets in healthy volunteers.Negligible Pharmacokinetic Interaction of Red Ginseng and Losartan, an Antihypertensive Agent, in Sprague-Dawley Rats.Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy particip
P2860
Q24630998-AE503823-6944-4390-8773-BD0939B45BDDQ24679467-F2C4802D-619B-426D-AB3A-62ABA4283329Q28084784-373A9D2D-EF2B-4B04-B51D-784297C5E194Q34030782-4F79F0C5-6697-421C-BB23-4E6F176D907DQ34293071-FDDE6B70-1CCD-4290-B1FA-8C832FE41604Q34328266-F41C1AA5-2F41-460F-986E-F854924D0790Q34408403-73A3C6F6-0677-44B4-B44C-FA191246BE39Q34409123-EEA8BC5B-64E5-4CDC-9AB7-B153776B5980Q34553835-0C9C1379-7025-4084-A21D-DA4266376AD0Q34582069-F97AB18B-59EE-4246-87DD-B65DDBCA43CFQ34778043-CC81C7B7-719D-498C-A4C9-4622DF16FF0EQ35083696-E63A4790-FCBA-4157-A140-D5BFC3EE6FD5Q35127335-137F4E14-EA31-4A96-ACB1-813EA9E09386Q35563528-731082DB-C403-4A8F-82AD-944FA093C7AAQ35570981-26F587C0-7F71-468B-B60F-117E5B28BB99Q35663423-F768C32F-E004-468E-8C9F-1E70B40A8377Q35825919-C8D10526-1EE2-4270-9AAF-CE119E0F6E13Q35960882-15772773-3949-4720-8351-CEF39935DC9AQ36007599-11EC7E53-7BA2-481C-9413-B944158329F2Q36065586-728F3C0E-8778-4C4E-9351-FC1D63D75178Q36282616-B57E1B66-E870-4924-B207-B726706817E9Q36303746-90BC6A03-AEAF-4DB9-B376-EF0A8C90348FQ36648850-CE57EAD7-FB8B-4150-BB15-28EEC7216889Q37058658-146B25CA-BC25-4918-8F45-5902AC317289Q37321412-63A2A5D4-DB25-4EAC-AA35-DE1F81713127Q37427926-0593C535-AC3E-434B-A2BC-653D5CC88B7BQ37583856-FA7F655D-35C8-4814-8C2E-55BDFE6C3F6AQ37596764-CA875B71-23AA-4B34-8B80-66957E1CA5B7Q37800414-55C78E48-029E-4339-8EE9-908F6E266C6FQ37907103-2AAA6D62-E35B-48C9-B069-062B6B6C53A2Q37993631-50019260-0EA5-4443-ACC6-4D3E5065ADACQ38122099-DF7AAE2B-25E0-45A5-895D-F16C593B0E85Q38132471-535184A2-9FE5-4A26-85C3-20DD96FBCB8AQ38815307-1EFD04FE-F7D2-4CBE-B0AA-D280F0C724A0Q38852053-964E2D0D-A16C-45B8-B2BC-6705685E04AFQ38937228-8955647A-3CCE-418D-B2F8-86ADB5F68A66Q39196166-ED86A226-0E33-4129-9997-12D6484CBF8DQ39895765-CAF5370C-4247-4D1B-AC7A-7747F600DBCCQ40378165-65B9DC71-71D3-419C-B722-CC94E0A8C217Q40831047-8E6B5164-9891-4F7A-BA03-833A43E11B5D
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Effects of food on clinical pharmacokinetics.
@ast
Effects of food on clinical pharmacokinetics.
@en
type
label
Effects of food on clinical pharmacokinetics.
@ast
Effects of food on clinical pharmacokinetics.
@en
prefLabel
Effects of food on clinical pharmacokinetics.
@ast
Effects of food on clinical pharmacokinetics.
@en
P1476
Effects of food on clinical pharmacokinetics.
@en
P2093
P304
P356
10.2165/00003088-199937030-00003
P577
1999-09-01T00:00:00Z
P6179
1029207686